At the news
? BEARISHIMPACT 7/10 8-K filed Sep 4, 2026 at 17:00 ET
Ionis Pharmaceuticals announced that its partner Novartis reported the Phase 3 Lp(a)HORIZON study of pelacarsen did not meet its primary endpoint of reducing cardiovascular events in patients with elevated Lp(a) and established cardiovascular disease. The trial enrolled 8,323 patients and achieved substantial Lp(a) lowering but failed to translate into cardiovascular risk reduction. This is a major clinical setback for Ionis's partnered pipeline asset.
- Phase 3 Lp(a)HORIZON study of pelacarsen did not meet its primary endpoint of reducing cardiovascular events (composite of CV death, non-fatal MI, non-fatal stroke, urgent coronary revascularization).
- Trial enrolled 8,323 patients with elevated Lp(a) and established cardiovascular disease.
- Pelacarsen substantially lowered Lp(a) levels but did not reduce cardiovascular risk.
- Pelacarsen demonstrated an acceptable safety profile.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access